Luminex Corporation (NASDAQ:LMNX) will begin trading ex-dividend on December 22, 2020. The quarterly dividend payment of $ 0.10 per share is scheduled to be paid on January 14, 2021. The dividend yield based on the latest trading day closing price was 1.64 percent. To secure the dividend payout, investors must buy the stock prior to the ex-dividend date of December 22, 2020.
Dividends History
wpDataTable with provided ID not found!Click Here For More Historical Dividends Of Luminex Corporation
Luminex Corporation recently reported third quarter financial results on November 5, 2020, after market close, the Austin based company recorded income for the third quarter of $ 0.04 per share, from the revenue of $ 106.06 million. The quarterly revenues up 34.82 percent compared with the same quarter last year. According to street consensus, LMNX was expected to report 3Q20 income of $ 0.20 per share from revenue of $ 105.02 million. The bottom line results missed street analysts by $ 0.16 or 80 percent, at the same time, top line results outshined analysts by $ 1.04 million or 0.99 percent.
Stock Performance
Shares of Luminex Corporation traded up $ 0.45 or 1.88 percent on Friday, reaching $ 24.33 with volume of 1.65 million shares. Luminex Corporation has traded high as $ 24.49 and has cracked $ 23.83 on the downward trend
According to the previous trading day, closing price of $ 24.33, representing a 15.87 % increase from the 52 week low of $ 20.61 and a 42.72 % decrease over the 52 week high of $ 41.69.
The company has a market capital of $ 1.16 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism.
